A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase

References

• Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian H M. The biology of chronic myeloid leukemia. N Engl J Med 1999; 341: 164–172
   PubMed Web of Science ®Google Scholar
• Sawyers C L. Chronic myeloid leukemia. N Engl J Med 1999; 340: 1330–1340
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Shan J, Smith T, Talpaz M, Kozuch P, Rios M B, et al. Response to therapy is independently associated with survival prolongation in chronic myelogenous leukemia in the blastic phase. Cancer 2001; 92: 2501–2507
   PubMed Web of Science ®Google Scholar
• Wadhwa J, Szydlo R M, Apperley J F, Chase A, Bua M, Marin D, et al. Factors affecting duration of survival after onset of blastic transformation of chronic myeloid leukemia. Blood 2002; 99: 2304–2309
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Cortes J, O'Brien S, Giles F J, Albitar M, Rios M B, et al. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Blood 2002; 99: 3547–3553
   PubMed Web of Science ®Google Scholar
• Sacchi S, Kantarjian H M, O'Brien S, Cortes J, Rios M B, Giles F J, et al. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients. Cancer 1999; 86: 2632–2641
   PubMed Web of Science ®Google Scholar
• Iacoboni S J, Plunkett W, Kantarjian H M, Estey E, Keating M J, McCredie K B, et al. High dose cytosine arabinoside: treatment and cellular pharmacology of chronic myelogenous leukemia blast crisis. J Clin Oncol 1986; 4: 1079–1088
   PubMed Web of Science ®Google Scholar
• Kantarjian H, Talpaz M, Kontoyiannis D, Gutterman J, Keating M J, Estey E H, et al. Treatment of chronic myelogenous leukemia in accelerated and blastic phase with daunorubicin, high-dose cytarabine and granulocyte-macrophage colony-stimulating factor. J Clin Oncol 1992; 10: 398–405
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, O'Brien S M, Cortes J, Giles F J, Faderl S, Issa J P, et al. Results of decitabine (5-aza-2′deoxycytidine) therapy in 130 patients with chronic myelogenous leukemia. Cancer 2003; 98: 522–528
   PubMed Web of Science ®Google Scholar
• Dutcher J P, Eudey L, Wiemick P H, Paietta E, Bennett J M, Arlin Z, et al. Phase II study of mitoxantrone and 5-azacitidine for accelerated and blast crisis of chronic myeloid leukemia: a study of the Eastern Cooperative Oncology Group. Leukemia 1992; 6: 770–775
   PubMed Web of Science ®Google Scholar
• Dann E J, Anastasi J, Larson R A. High-dose cladribine therapy for chronic myelogenous leukemia in the accelerated or blast phase. J Clin Oncol 1998; 16: 1498–1504
   PubMed Web of Science ®Google Scholar
• Montefusco E, Petti M C, Alimena G, Latagliata R, Celesti F, Capria S, et al. Etoposide, intermediate-dose cytarabine, and carboplatin (VAC): a combination therapy for the blastic phase of chronic myelogenous leukemia. Ann Oncol 1997; 8: 175–179
   PubMed Web of Science ®Google Scholar
• Schiffer C A, DeBellis R, Kasdorf H, Wiernik P H. Treatment of the blast crisis of chronic myelogenous leukemia with 5-azacitidine and VP-16-213. Cancer Treat Rep 1982; 66: 267–271
   PubMedGoogle Scholar
• Gambacorti-Passerini C, le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, et al. Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 1997; 23: 380–394
   PubMed Web of Science ®Google Scholar
• Le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, et al. In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor. J Natl Cancer Inst 1999; 91: 163–168
   PubMed Web of Science ®Google Scholar
• Sawyers C L, Hochhaus A, Feldman E, Goldman J M, Miller C B, Ottmann O G, et al. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 2002; 99: 3530–3539
   PubMed Web of Science ®Google Scholar
• Donato N J, Wu J Y, Stapley J, Lin H, Arlinghaus R, Aggarwal B B, et al. Imatinib mesylate resistance through BCR-ABL independence in chronic myelogenous leukemia. Cancer Res 2004; 64: 672–677
   PubMed Web of Science ®Google Scholar
• Gorre M E, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001; 293: 876–880
   PubMed Web of Science ®Google Scholar
• La Rosee P, Johnson K, Corbin A S, Stoffregen E P, Moseson E M, Willis S, et al. In vitro efficacy of combined treatment depends on the underlying mechanism of resistance in imatinib-resistant Bcr-Abl-positive cell lines. Blood 2004; 103: 208–215
   PubMed Web of Science ®Google Scholar
• Nardi V, Azam M, Daley G Q. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol 2004; 11: 35–43
   PubMed Web of Science ®Google Scholar
• Thiesing J T, Ohno-Jones S, Kolibaba K S, Druker B J. Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells. Blood 2000; 96: 3195–3199
   PubMed Web of Science ®Google Scholar
• Topay J, Zeller W J, Fruehauf S. Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. Leukemia 2001; 15: 342–347
   PubMed Web of Science ®Google Scholar
• Liu W M, Stimson L A, Joel S P. The in vitro activity of the tyrosine kinase inhibitor STI571 in BCR-ABL positive chronic myeloid leukaemia cells: synergistic interactions with anti-leukaemic agents. Br J Cancer 2002; 86: 1472–1478
   PubMed Web of Science ®Google Scholar
• La Rosee P, O'Dwyer M E, Druker B J. Insights from pre-clinical studies for new combination treatment regimens with the Bcr-Abl kinase inhibitor imatinib mesylate (Gleevec/Glivec) in chronic myelogenous leukemia: a translational perspective. Leukemia 2002; 16: 1213–1219
   PubMed Web of Science ®Google Scholar
• Thomas D A, Faderl S, Cortes J, O'Brien S, Giles F J, Kornblau S M, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood 2004; 103: 4396–4407
   PubMed Web of Science ®Google Scholar
• Kantarjian H M, Keating M J, Talpaz M, Walters R S, Smith T L, Cork A, et al. Chronic myelogenous leukemia in blast crisis. Analysis of 242 patients. Am J Med 1987; 83: 445–454
   PubMed Web of Science ®Google Scholar
• Bortin M, Horowitz M, Rowlings P, Rimm A A, Sobocinski K A, Zhang M J, et al. for the Advisory Committee of the International Bone Marrow Transplant Registry. 1993 progress report from International Bone Marrow Transplant Registry. Bone Marrow Transplant 1993; 12: 97–104
   PubMed Web of Science ®Google Scholar
• Issa J P, Gharibyan V, Cortes J, Jelinek J, Morris G, Verstovsek S, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005; 23: 3948–3956
   PubMed Web of Science ®Google Scholar
• Radich J P, Olavarria E, Apperley J F. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia. Hematol Oncol Clin North Am 2004; 18: 685–702
   PubMed Web of Science ®Google Scholar